The Blood and Marrow Transplant (BMT) program at Children’s Hospital of Philadelphia has been serving the needs of patients since 1976. Our program is recognized for its quality, service, innovative approaches and excellent patient outcomes. We have one of the highest volumes of pediatric blood and marrow transplant-eligible patients among BMT providers nationwide.
Our state-of-the-art facility offers all transplant services at a single location where patient comfort and safety is the priority. This includes the inpatient unit, outpatient clinic, collection facility where we obtain the stem cells used in treatment, and a laboratory where those cells are prepared for the transplant.
Children’s Hospital of Philadelphia is one of the few pediatric blood and marrow transplant centers to have a Good Manufacturing Process (GMP) stem cell processing laboratory, the highest standard in drug and biologic manufacturing in the eyes of the Food and Drug Administration (FDA). We also have the most advanced immunogenetics (tissue typing) laboratory on site, which uses cutting-edge genomic sequencing techniques to provide detailed profiles of your child’s disease, which aids in treatment planning.
Our institution attained Magnet® recognition as part of the American Nurses Credentialing Center’s (ANCC) Magnet Recognition Program®. This voluntary credentialing program for hospitals recognizes excellence in nursing. Our nurses are certified as chemotherapy and biotherapy providers. CHOP BMT nurses are formally trained and experienced in the management of pediatric patients receiving cellular therapy, and inpatient nurses are also experienced oncology nurses.
For children who will need an allogeneic (non-self) transplant and do not have a fully matched family member, we have many options. Children’s Hospital is a member of the National Marrow Donor Program (NMDP), which connects patients without a matched family member with appropriate, well-matched donors from around the country. Our center statistics show that we find a suitable alternative faster than the national average for BMT providers. Our program also enrolls qualified patients in clinical trials as needed to allow for use of mismatched donors.